Performance of Different Combination Models of High-Risk HPV Genotyping in Triaging Chinese Women With Atypical Squamous Cells of Undetermined Significance
Overview
Authors
Affiliations
The purpose of this study was to evaluate the effect of different combination models of high-risk human papilloma viruses (HPV) genotyping in triaging Chinese women with atypical squamous cells of undetermined significance (ASCUS). We established a screening cohort of 3,997 Chinese women who underwent cervical cytology and HPV genotyping test. Women with ASCUS cytology underwent punch biopsy under colposcopy/endocervical curettage. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of different combination models of HR-HPV genotyping calculated that cervical intraepithelial neoplasia 2 or higher (CIN2+) on histology were endpoints. Of the full sample, 393 women had ASCUS. Among ASCUS women with a CIN2 lesion, the prevalence for HPV were 40.0% (type 16), 10.0% (type 18), 0.0% (type 33), 30.0% (type 52), 40.0% (type 58), and 30.0% (other nine types). For ASCUS women with a CIN3 lesion, the prevalence for HPV were 68.4% (type 16), 15.8% (type 18), 10.5% (type 33), 31.6% (type 52), 15.8% (type 58), and 36.8% (other nine types). Combination model including HPV16/18/33/52/58 for predicting CIN2+ lesion in women with ASCUS had relatively higher sensitivity [93.1% (78.0, 98.1)], specificity [75.8% (71.2, 79.9)], PPV [23.5% (16.7, 32.0)], and NPV [99.3% (97.4, 99.8)] than other combination models. Moreover, the referral rate of HPV16/18/33/52/58 (29.3%) was lower than HR-HPV (36.1%). The study demonstrates that specific HR-HPV types HPV16/18/33/52/58 may be an effective strategy in ASCUS triage. This improves the subsequent selection of ASCUS patients.
Yang H, Hao Y, Niu M, Zheng J, Jia X, Zhang S Front Oncol. 2024; 14:1416116.
PMID: 39439955 PMC: 11494462. DOI: 10.3389/fonc.2024.1416116.
Li B, Dong L, Wang C, Li J, Zhao X, Dong M Front Cell Infect Microbiol. 2023; 13:1123260.
PMID: 36875525 PMC: 9978476. DOI: 10.3389/fcimb.2023.1123260.
Wang W, Zhang H, Lin L, Yang A, Yang J, Zhao W J Cancer. 2021; 12(10):2815-2824.
PMID: 33854582 PMC: 8040879. DOI: 10.7150/jca.55771.
Pan D, Dong B, Gao H, Mao X, Xue H, Sun P Risk Manag Healthc Policy. 2020; 13:1747-1756.
PMID: 33061708 PMC: 7522426. DOI: 10.2147/RMHP.S270265.